BioSpace News Archive

iStent inject Achieved 42% Reduction in Mean IOP to 14.6 mmHg and 82% Reduction in Mean Medications to 0.55 at 3 Years Postoperative with Favorable Safety Profile in Real-World Cohort

Akebia Therapeutics, Inc. granted 14 newly-hired employees options to purchase an aggregate of 344,200 shares of Akebia’s common stock on May 31, 2019, including an option to purchase 250,000 shares granted to Dell Faulkingham, Akebia’s newly-hired Senior Vice President, Chief Commercial Officer.

Sierra Oncology, Inc. announced that it has obtained regulatory clarity with the U.S. Food and Drug Administration (FDA) concerning the design of a Phase 3 clinical trial for momelotinib intended to support potential registration of this differentiated drug candidate for the treatment of previously JAK inhibitor treated myelofibrosis patients.

Planned Parenthood of Greater New York (PPGNY) moves one step closer to expanding safe and affordable health care to more New Yorkers, and people across the country

Targeting CXCR4 May Impact Aggressive Metastatic Behavior of Cancer Cells, Which May be Related to a Poor Prognosis

DionyMed Brands Inc. announced that due to a change in application of an accounting treatment, its predecessor corporation, DionyMed Holdings Inc., has completed and filed the restatement of its audited financial statements for the periods ended February 28, 2018 and July 31, 2018, and the interim quarters ended May 31, 2018, August 31, 2018 and November 30, 2018.

Phase 3 HOPE Study 24-Week Efficacy Results from Full Patient Cohort to be Presented During Presidential Symposium

Pre-NDA Meeting Completed and Company Announces FDA Agreed to a Rolling Submission of New Drug Application for Voxelotor for the Potential Treatment of Sickle Cell Disease

Company Plans to Submit NDA for Voxelotor Under FDA Accelerated Approval Pathway Later This Year

37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019, at 11:30 a.m. Pacific Time.